Demonstration of functional similarity of a biosimilar adalimumab SB5 to Humira®

EMA, 2014

EMA, 2014

EMA, 2014

Roger, 2006, Biosimilars: how similar or dissimilar are they?, Nephrology (Carlton), 11, 341, 10.1111/j.1440-1797.2006.00594.x

McCamish, 2011, Worldwide experience with biosimilar development, mAbs, 3, 209, 10.4161/mabs.3.2.15005

Li, 2015, Considerations in the early development of biosimilar products, Drug Discov Today, 20, 1, 10.1016/j.drudis.2014.12.017

FDA, 2015

FDA, 2015

Markus, 2017, Developing the totality of evidence for biosimilars: regulatory considerations and building confidence for the Healthcare community, BioDrugs, 31, 175, 10.1007/s40259-017-0218-5

Bradley, 2008, TNF-mediated inflammatory disease, J Pathol, 214, 149, 10.1002/path.2287

Choy, 2012, Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis, Rheumatology (Oxford), 51, 10.1093/rheumatology/kes113

Brennan, 2008, Evidence that cytokines play a role in rheumatoid arthritis, J Clin Invest, 118, 3537, 10.1172/JCI36389

Baumgart, 2007, Inflammatory bowel disease : clinical aspects and established and evolving therapies, Lancet, 369, 1641, 10.1016/S0140-6736(07)60751-X

FDA, 2017

Tsong, 2017, Development of statistical methods for analytical similarity assessment, J Biopharm Stat, 27, 197, 10.1080/10543406.2016.1272606

Horiuchi, 2010, Transmembrane TNF-α: structure, function and interaction with anti-TNF agents, Rheumatology, 49, 1215, 10.1093/rheumatology/keq031

Tracey, 2008, Tumor necrosis factor antagonist mechanisms of action: a comprehensive review, Pharmacol Ther, 117, 244, 10.1016/j.pharmthera.2007.10.001

Mitoma, 2008, Mechanisms for cytotoxic effects of anti–tumor necrosis factor agents on transmembrane tumor necrosis factor α–expressing cells: comparison among infliximab, etanercept, and adalimumab, Arthritis Rheum, 58, 1248, 10.1002/art.23447

Nimmerjahn, 2007, Fc-receptors as regulators of immunity, Adv Immunol, 96, 179, 10.1016/S0065-2776(07)96005-8

Deo, 1997, Clinical significance of IgG Fc receptors and Fc gamma R-directed immunotherapies, Immunol Today, 18, 127, 10.1016/S0167-5699(97)01007-4

Roopenian, 2007, FcRn: the neonatal Fc receptor comes of age, Nat Rev Immunol, 7, 715, 10.1038/nri2155

Peake, 2013, Mechanisms of action of anti-tumor necrosis factor α agents in Crohn's disease, Inflamm Bowel Dis, 19, 1546, 10.1097/MIB.0b013e318281333b

Arora, 2009, Differences in binding and effector functions between classes of TNF antagonists, Cytokine, 45, 124, 10.1016/j.cyto.2008.11.008

Vos, 2011, Anti-Tumor necrosis factor-α antibodies induce regulatory macrophages in an Fc region-dependent manner, Gastroenterology, 140, 221, 10.1053/j.gastro.2010.10.008

Reusch, 2015, Fc glycans of therapeutic antibodies as critical quality attributes, Glycobiology, 25, 1325, 10.1093/glycob/cwv065

Suzuki, 2010, Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR, J Immunol, 184, 1968, 10.4049/jimmunol.0903296

Shin, 2017, A randomized phase I comparative pharmacokinetic study comparing SB5 with reference adalimumab in healthy volunteers, J Clin Pharm Therapeut, 42, 672

Weinblatt, 2018, Phase III randomized study of SB5, an adalimumab biosimilar, versus reference adalimumab in patients ith moderate-to-severe rheumatoid arthritis, Arthritis Rheum, 70, 40, 10.1002/art.40336